IDEXX Laboratories, Inc. vs Zillow Group Inc Class C — how do they compare? IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B), while Zillow Group Inc Class C trades at $29 (market cap $6.59B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.1× Zillow Group Inc Class C's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 9,134,294). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Zillow Group Inc Class C for 38 Days on average.
| IDXX | Z | |
|---|---|---|
Market Cap | $40.43B | $6.59B |
Volume | 692,164 | 9,134,294 |
Sector | Health | Media |
52-Week High | $766.68 | $78.04 |
52-Week Low | $504.70 | $27.13 |
Typical Hold Time | 46 Days | 38 Days |
Enterprise Value | $41.32B | $6.47B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Zillow Group (Z) trades at $28.84, up 5.72% in the last session, showing strong momentum despite mixed technical signals. The company has demonstrated improving fundamentals with revenue growing from $2.2B in 2024 to $2.6B in 2025, turning a net loss of $112M into a $23M profit. Recent earnings show beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Analyst sentiment is divided with a $60.33 consensus price target representing significant upside potential from current levels.
Zillow presents a compelling growth story with improving profitability and strong analyst targets, but faces headwinds from housing market volatility and rising mortgage rates. The stock's high P/E ratio of 126.83 reflects growth expectations, while technical indicators show conflicting signals with bullish overall momentum but bearish moving averages. The resolution of the FTC lawsuit removes regulatory overhang, but competition with Compass and market sensitivity to interest rates remain key risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →